EPILEPSY STUDY CONSORTIUM INC C/O … - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2006

Legal Domicile

Principal Officer

JAMES LINTOTT

Phone

7034379720

Tax Period

2024-01-01 to 2024-12-31

EPILEPSY STUDY CONSORTIUM INC C/O STERLING FOUNDATION MANAGEMENT LLC, founded in 2006, is a community nonprofit in the Diseases & Disorders sector that reported $2.5M in total revenue in fiscal year 2024. Revenue fell 26% from the prior year — a significant decline worth monitoring. Expenses of $2.2M left a modest 11% surplus.

Mission

ACCELERATING THE DEVELOPMENT OF NEW THERAPIES IN EPILEPSY TO IMPROVE PATIENT CARE THROUGH RESEARCH.

Program Service Accomplishments

Program 1

Expenses: $1,432,788 Revenue: $1,919,904

CONSULTING - MADE AVAILABLE VAST EPILEPSY EXPERTISE WHICH WAS UTILIZED FOR ADVISORY BOARDS AND INDEPENDENT CONSULTING ACTIVITY. PROVIDED STUDY DESIGN CONSULTATION ON A NUMBER OF PROTOCOLS. DEVELOPED AND IMPLEMENTED EDUCATIONAL TOOLS FOR USE IN CLINICAL TRIALS TO ENSURE ENROLLMENT OF APPROPRIATE SUBJECTS. CENTRAL REVIEW OF DOCUMENTATION TO CONFIRM ELIGIBILITY FOR PATIENTS IN CLINICAL TRIALS. DEVELOPED SEVERAL PROOF OF PRINCIPLE PROTOCOLS WHICH ARE AVAILABLE TO CLIENTS. IMPLEMENTED THE PREVIOUSLY DESIGNED PROOF OF PRINCIPLE STUDY TO ASSESS PHOTOSENSITIVE EPILEPSY INCLUDING SITE TRAINING.

Program 2

Expenses: $731,363

HUMAN EPILEPSY PROJECT - CONTINUING TO ANALYZE DATA FROM HEP 1 & HEPS 2 STUDIES. OVERSEE AND COORDINATE THE FINANCIAL ASPECTS OF THE HEP3 STUDY. TESC MANAGES HEP3 STUDYS LIFE CYCLE FOR NYU, OVERSEES...

Program 3

Expenses: $20,558

TRIAL DESIGNS - PREPARE AND ORGANIZE MULTINATIONAL SYMPOSIUM ON EPILEPSY TRIAL DESIGN AND IMPLEMENTATION.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $512,456

Program Service Revenue $1,919,904

Investment Income $60,181

Other Revenue $0

TOTAL REVENUE $2,492,541

Expense Breakdown

Grants Paid $119,000

Salaries & Benefits $882,849

Fundraising Expenses $0

Program Expenses $2,184,709

Other Expenses $1,219,289

TOTAL EXPENSES $2,221,138

Year-over-Year Comparison

	2024	2023	Change
Revenue	$2,492,541	$3,371,798	-0.3%
Expenses	$2,221,138	$1,701,465	+0.3%
Net Income	$271,403	$1,670,333	-0.8%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✓ Conflict of Interest Policy

✓ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$390,953

Total Directors

$422,208

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
JAMES LINTOTT ESQ	TREASURER	1.00	Officer Director	$0	$0	$0
MICHAEL SPERLING MD	DIRECTOR	1.00	Director	$4,228	$0	$4,228
JACQUELINE FRENCH MD	PRESIDENT	5.00	Officer Director	$0	$0	$0
DENNIS DLUGOS MD	VICE PRESIDENT	1.00	Officer Director	$0	$0	$0
BREE DIVENTURA	CO-EXECUTIVE DIRECTOR	40.00	Officer Director	$233,530	$7,006	$240,536
DANIEL FRIEDMAN MD	VICE PRESIDENT	1.00	Officer Director	$0	$0	$0
GREGORY KRAUSS MD	DIRECTOR	1.00	Director	$4,875	$0	$4,875
DAWN ELIASHIV MD	DIRECTOR	1.00	Director	$0	$0	$0
PAVEL KLEIN MD	DIRECTOR	1.00	Director	$0	$0	$0
SUDHA KESSLER MD	DIRECTOR	1.00	Director	$0	$0	$0
ROBERT WECHSLER MD PHD	DIRECTOR	1.00	Director	$0	$0	$0
CLAUDE STERIADE MD	DIRECTOR	1.00	Director	$0	$0	$0
MICHAEL GELFAND MD	DIRECTOR	1.00	Director	$22,152	$0	$22,152
JENNIE MINNICK	EXECUTIVE COMMITTEE MEMBER	1.00	Director	$0	$0	$0
MERYL J LOZANO	CO-EXECUTIVE DIRECTOR	40.00	Officer Director	$150,417	$0	$150,417
TRACY L DE VITO	EMPLOYEE	40.00	Highest	$110,004	$0	$110,004

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$2,492,541	$2,221,138	$3,725,581	$271,403
2023	$3,371,798	$1,701,465	$3,454,178	$1,670,333
2022	$2,128,414	$1,917,817	$1,783,845	$210,597
2021	$1,805,835	$1,314,277	$1,573,248	$491,558
2020	$1,622,918	$2,177,935	$1,081,690	$-555,017
2019	$1,989,035	$2,878,662	$1,636,707	$-889,627
2018	$2,414,102	$3,238,445	$2,526,334	$-824,343

EPILEPSY STUDY CONSORTIUM INC C/O STERLING FOUNDATION MANAGEMENT LLC